New targeted vaccine combo tested for rare liver cancer
NCT ID NCT07430202
Summary
This early-stage study is testing a new combination treatment for people with advanced fibrolamellar hepatocellular carcinoma (FLC), a rare type of liver cancer. The treatment combines a personalized vaccine that targets a specific cancer marker with three other drugs designed to help the immune system fight the cancer. The main goals are to see if this four-part combination is safe and if it can shrink tumors or stop them from growing.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER (FIBROLAMELLAR HEPATOCELLULAR CANCER (FLC)) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Johns Hopkins SKCCC
Baltimore, Maryland, 21231, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.